Sign in

OTLC on OTC

Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc. is an American pharmaceutical preparations company based in Aguora Hills.1 Its shares trade on OTC under the symbol OTLC.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Silo Pharma, Inc., Inovio Pharmaceuticals or Benitec Biopharma Ltd, or pick any stock.

  • TickerOTLC on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersAguora Hills, California1
  • Incorporated inDE2
  • Business address29397 Agoura Rd., #107, Aguora Hills, Ca 913012
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

COVID-19, on its own and in conjunction with other compounds. This is being advanced through our JV.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-9497.2%Operating margin4
-11290.1%Net margin4
-65.2%Return on equity4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development6¢$61.1K
  • Interest94¢$1.0M

Out of $70.0K in revenue.45 The company lost money this year.

Financial statements

Revenue64$70.0K in 2023−96% since 2020
0$500.0K$1.0M$1.5M$2.0M2020: $1.7M$1.7M20202023: $70.0K$70.0K2023−96%
Operating income76854-$6.6M in 2023+54% since 2019
-$10.0M-$7.5M-$5.0M-$2.5M02019: -$4.3M-$4.3M20192020: -$7.6M-$7.6M2020+76%2021: -$9.1M-$9.1M2021+20%2022: -$9.7M-$9.7M2022+7%2023: -$6.6M-$6.6M2023−32%
Net income76854-$7.9M in 2023+19% since 2019
-$10.0M-$5.0M0$5.0M$10.0M2019: -$6.6M-$6.6M20192020: -$9.5M-$9.5M2020+43%2021: -$9.4M-$9.4M2021−1%2022: $5.1M$5.1M20222023: -$7.9M-$7.9M2023

Every line of the income statement as filed: the last 2 fiscal years, latest first.11

Period ending2025-12-312024-12-31
Research and development$4.4K
General and administrative$3.2M$376.0K
Goodwill impairment (See note 2 and 3)$3.2M
Total operating expenses$3.2M$3.6M
Income/(Loss) from operations-$3.2M-$3.6M
Change in fair value of investment in GMP Bio$365.3M
Interest expense, net-$885.5K-$857.7K
Reimbursement for expenses - related party$22.9K
Change in fair value of derivative on debt$353.6K-$280.4K
Loss on debt conversion-$1.1M-$88.3K
Miscellaneous income$5.6K
Total other income (expense)$363.8M-$1.2M
Net income (loss) before income taxes$360.6M-$4.8M
Provision for income taxes-$111.5M
Net income (loss) after income taxes before non-controlling interests$249.0M-$4.8M
Net loss attributable to non-controlling interests-$254.9K-$255.5K
Net income (loss) attributable to Oncotelic Therapeutics, Inc.$249.3M-$4.5M
Basic net income (loss) per share attributable to common stock$0.59$0.01
Basic weighted average common stock outstanding421.0M shares404.4M shares
Basic and diluted net income (loss) per share attributable to common stock$0.59-$0.01
Basic and diluted weighted average common stock outstanding422.2M shares404.4M shares

Compare Oncotelic Therapeutics, Inc. with another company

What it owns

What Oncotelic Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$2.8M11 Dec 31, 2025$2.8M11 Dec 31, 20240%

Properties, in its own words

Our office is located in Agoura Hills, California, where we lease about 2,000 square feet of general office space. The lease for this office is on a month-to-month basis. We consider our office space to be adequate for our current needs. We believe that other suitable office space would be available if we moved to a different location upon the expiration of our current lease.

Item 2 of the 10-K filed Apr 15, 2026.3

Leadership

Who has led Oncotelic Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Richard Chin2006–2008
  2. John A. Kollins2008–2009
  3. Peter Langecker2010–2013
  4. David Chaplin2014
  5. William D. Schwieterman2015–2018
  6. Vuong Trieu2019–now

Chair

  1. Vuong Trieu2019–now

President

  1. Richard Chin2006–2008
  2. David Chaplin2014
  3. William D. Schwieterman2015–2018

Chief financial officer

  1. James B. Murphy2006–2010
  2. David Louis Johnson2012
  3. Barbara Riching2013–2015
  4. Matthew M. Loar2015–2018

Chief operating officer

  1. Scott Young2006
2010201520202025
Board members and other officers (33)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerSHAH AMIT named Jul 22, 202652
  • The above is the Chief Financial Officer of Oncotelic and of EdgePoint AI, Inc.Amit Shah named Jul 13, 202353
  • DirectorSTEVEN KING named Jul 22, 202652

Former names

  • MATEON THERAPEUTICS INCJun 17, 2016 to Mar 26, 20212
  • OXIGENE INCOct 24, 1996 to Jun 3, 20162

Timeline

  1. Oct 13, 20268-K Other events54
  2. Aug 4, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares55
  3. Jul 14, 20268-K Unregistered sale of shares; Executive or director change56
  4. Jul 14, 20268-K Other events57
  5. Jun 29, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares58
  6. May 5, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares59
  7. Apr 16, 20268-K Other events60
  8. Apr 2, 20268-K Entered a material agreement; Other events61
  9. Mar 30, 20268-K Other events62
  10. Mar 30, 20268-K Other events63
  11. Jan 29, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares64
  12. Jan 26, 20268-K Entered a material agreement; Executive or director change65
  13. May 2, 2019New chief executive Vuong Trieu becomes CEO12
  14. May 29, 2015New chief executive William D. Schwieterman becomes CEO13
  15. May 19, 2014New chief executive David Chaplin becomes CEO14
  16. Apr 29, 2010New chief executive Peter Langecker becomes CEO15
  17. Dec 18, 2008New chief executive John A. Kollins becomes CEO16
  18. Jul 7, 2006New chief executive Richard Chin becomes CEO17

Calendar

When it reported results

  1. Nov 24, 2021Reported quarterly or annual results66

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

136 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 55 major events, 25 insider forms, 3 private raises, 32 other. The latest 20:

  1. Oct 13, 20268-K EDGAR
  2. Aug 13, 202610-Q EDGAR
  3. Aug 4, 20268-K EDGAR
  4. Jul 23, 20264 EDGAR
  5. Jul 22, 2026D EDGAR
  6. Jul 21, 20264 EDGAR
  7. Jul 14, 20268-K EDGAR
  8. Jul 14, 20268-K EDGAR
  9. Jul 14, 20264 EDGAR
  10. Jul 14, 20264 EDGAR
  11. Jul 14, 20264 EDGAR
  12. Jul 14, 20264 EDGAR
  13. Jul 2, 20264 EDGAR
  14. Jun 29, 20268-K EDGAR
  15. Jun 24, 20264 EDGAR
  16. Jun 22, 20264 EDGAR
  17. Jun 17, 20264 EDGAR
  18. May 14, 202610-Q EDGAR
  19. May 5, 20268-K EDGAR
  20. Apr 16, 20268-K EDGAR

The 136 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

25 open-market trades by officers, directors and large owners since October 2021: 25 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 1, 2026Trieu VuongCHAIRMAN AND CEOBuy240,000$0.04$9.6KForm 4
Jun 24, 2026Trieu VuongCHAIRMAN AND CEOBuy115,000$0.05$5.8KForm 4
Jun 23, 2026Trieu VuongCHAIRMAN AND CEOBuy75,000$0.05$3.8KForm 4
Jun 22, 2026Trieu VuongCHAIRMAN AND CEOBuy65,000$0.05$3.2KForm 4
Jun 22, 2026Shah Amit B.CFOBuy20,000$0.05$1.0KForm 4
Jun 17, 2026Trieu VuongCHAIRMAN AND CEOBuy239,759$0.04$9.6KForm 4
Jun 15, 2026Trieu VuongCHAIRMAN AND CEOBuy96,000$0.05$4.8KForm 4
Jul 10, 2025Trieu VuongCHAIRMAN AND CEOBuy104,000$0.01$1.0KForm 4
Jul 9, 2025Trieu VuongCHAIRMAN AND CEOBuy1$0.01Form 4
Jul 8, 2025Trieu VuongCHAIRMAN AND CEOBuy94,736$0.01$947Form 4
Jan 31, 2025Trieu VuongCHAIRMAN AND CEOBuy63,775$0.03$1.9KForm 4
Jan 30, 2025Trieu VuongCHAIRMAN AND CEOBuy100,003$0.03$3.0KForm 4
Jan 29, 2025Trieu VuongCHAIRMAN AND CEOBuy183,066$0.03$5.5KForm 4
Nov 22, 2024Trieu VuongCHAIRMAN AND CEOBuy298,499$0.03$9.0KForm 4
Aug 23, 2024Trieu VuongCHAIRMAN AND CEOBuy500,000$0.02$10.0KForm 4
Jun 29, 2023Trieu VuongCHAIRMAN AND CEOBuy425,000$0.02$8.5KForm 4
Jun 28, 2023Trieu VuongCHAIRMAN AND CEOBuy75,000$0.03$2.2KForm 4
Jun 16, 2023Trieu VuongCHAIRMAN AND CEOBuy100,000$0.03$3.0KForm 4
Jun 14, 2023Trieu VuongCHAIRMAN AND CEOBuy400,000$0.03$12.0KForm 4
May 26, 2023Trieu VuongCHAIRMAN AND CEOBuy126,888$0.03$3.8KForm 4

All 25 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 10, 2026Raised $711,840 in a private offering of equity Form D: 33 investors so far Form D
  2. Dec 4, 2025Raised $275,000 in a private offering of securities Form D: $12.5 million offered in all Form D
  3. Jul 13, 2023Filed a private offering of debt Form D: $5 million offered in all Form D

SEC filer profile

How Oncotelic Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROncotelic Therapeutics, Inc.1
  • CIK0000908259
  • Employer ID (EIN)13-36791683
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address29397 Agoura Rd., #107, Aguora Hills, CA 913011
  • Phone650-635-70001
  • Shares outstanding457,512,796 as of Aug 13, 20269
  • Public float$9.1M as of Jun 30, 20253
  • AuditorRose, Snyder & Jacobs LLP, Encino, CA PCAOB ID 468; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceApr 4, 19961
  • Filings1,216 in all: 8-K (378), 4 (249), 10-Q (92), 3 (34), 10-K (30), DEF 14A (29), 424B3 (27), EFFECT (25)1
    All 49 form types

    SC 13G/A (23), UPLOAD (23), 4/A (21), 5 (20), CORRESP (20), 424B5 (16), 8-K/A (16), PRE 14A (16), S-3 (16), S-8 (16), DEFA14A (13), SC 13G (13), 10-K/A (12), NT 10-Q (12), POS AM (10), S-3/A (10), 425 (9), NT 10-K (9), S-1/A (9), SC 13D/A (9), D (8), SC 13D (8), S-1 (7), 10-Q/A (6), FWP (4), CT ORDER (3), DEFR14A (3), PRER14A (3), 424B2 (2), ARS (2), REGDEX (2), RW (2), 25-NSE (1), 424B4 (1), 424B7 (1), 8-A12G (1), PRE 14C (1), PRER14C (1), S-1MEF (1), S-4 (1), S-8 POS (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Jun 25, 2020
    Latest 8-K (8-K) Oct 13, 2026

Risk factors and legal proceedings

The risks Oncotelic Therapeutics, Inc. names in Item 1A of its 10-K filed Apr 15, 2026: 37 risks under these headings, as written.3

  • RISKS RELATED TO OUR INVESTMENTS
  • Our principal asset is our minority investment in a JV, which makes an evaluation of our financial condition more difficult for investors.
  • The JV is a pre-revenue life sciences venture that is difficult to value, and changes in development results, market conditions, valuation methodology or assumptions could result in material impairment charges, significant volatility in our financial results and/or a material reduction in our reported asset values.
  • A material amount of our assets represents intangible assets, and our net income would be reduced, or our net loss would be increased, if our intangible assets became impaired.
  • RISKS RELATED TO OUR FINANCIAL CONDITION
  • If we are unable to obtain additional funding, we may be forced to cease operations.
  • The JV may not be able to successfully complete its planned IPO which could reduce its access to capital and may impair the value of our investment in the JV.
  • Due in part to our limited financial resources, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable indications or therapeutic areas for our product candidates, and we may be unable to pursue and complete the clinical trials that we would like to pursue and complete.
  • RISKS RELATED TO OUR BUSINESS AND INDUSTRY
  • We may encounter difficulties in expanding our operations successfully if and when we evolve from a company that is primarily involved in clinical development to a company that is also involved in commercialization.
  • We have no manufacturing capacity and have relied on, and expect to continue to rely on, third-party manufacturers to produce our product candidates.
  • Our product candidates have not completed clinical trials and may never demonstrate sufficient safety and efficacy in order to do so.
The other 28 risks
  • Our industry is highly competitive, and our product candidates may become obsolete.
  • If clinical trials or regulatory approval processes for our product candidates are prolonged, delayed or suspended, we may be unable to out-license or commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay or prevent our receipt of any proceeds from potential license agreements or product sales.
  • If physicians and patients do not accept our future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any.
  • The uncertainty associated with pharmaceutical reimbursement and related matters may adversely affect our business.
  • We rely on a limited number of employees at the JV to manage and operate our business.
  • We depend on our executive officers and principal consultants and the loss of their services could materially harm our business.
  • Our business and operations could suffer in the event of system failures.
  • REGULATORY AND LEGAL RISKS
  • If we are unable to obtain required regulatory approvals, we will be unable to market and sell our product candidates.
  • If we or the third parties on which we rely for the conduct of our clinical trials do not perform our clinical trial activities in accordance with good clinical practices and related regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.
  • The use of our products may result in product liability exposure, and it is uncertain whether our insurance coverage will be sufficient to cover all claims.
  • We and the JV intend to take advantage of regulatory pathways to accelerate product candidate development, and failure to secure such pathways would result in increased product development costs and longer regulatory approval as we seek to commercialize our product candidates.
  • We have been granted orphan drug status for certain of our product candidates and may seek orphan drug status for additional indications for those product candidates or for additional product candidates. We may be unsuccessful in maintaining orphan drug exclusivity for our product candidates and may be unsuccessful in our efforts to seek orphan drug status and orphan drug exclusivity.
  • Our product candidates will remain subject to ongoing regulatory review even if they receive marketing approval, and if we fail to comply with continuing regulations, we could lose these approvals and the sale of any approved commercial products could be suspended.
  • Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
  • RISKS RELATED TO INTELLECTUAL PROPERTY
  • We depend extensively on the patents and proprietary technology we license from others, and we must maintain these licenses in order to preserve our business.
  • We depend on patents and proprietary technology in the course of our business, and we must protect those assets in order to preserve our business.
  • RISKS RELATED TO OUR COMMON STOCK
  • The price of our common stock is volatile and is likely to continue to fluctuate due to reasons beyond our control.
  • A limited trading market may increase the volatility of trading in our stock.
  • Our common stock is currently subject to the “Penny Stock” Rules of the SEC and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.
  • We may not be able to achieve secondary trading of our stock in certain states because our common stock is no longer nationally traded, which could subject our stockholders to significant restrictions and costs.
  • We may not be able to uplist our stock to a national stock exchange which could subject our stockholders to significant restrictions and costs.
  • If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results. As a result, current and potential stockholders could lose confidence in our financial reporting, which could harm our business and the trading price of our stock.
  • Issuance of additional equity securities may adversely affect the market price of our common stock.
  • We have no plans to pay dividends on our common stock, and you may not receive funds without selling your common stock.
  • RISKS RELATED TO MAST HILL EQUITY LINE
  • Mast Hill’s sales of our Shares into the open market may cause material decreases in our stock price.
  • Funding from our Equity Purchase Agreement with Mast Hill will be limited by our current shares outstanding and may be insufficient to fund our operations or to implement our strategy.
  • The sale or issuance of our common stock to Mast Hill at a discount may cause substantial dilution and the resale of the shares of common stock by Mast Hill into the public market, or the perception that such sales may occur, could cause the price of our common stock to fall.
  • We may use the net proceeds from sales of our common stock to Mast Hill pursuant to the Equity Purchase Agreement in ways with which you may disagree.
  • Cautionary Note

Legal proceedings

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Historically, the outcome of all such legal proceedings has not, in the aggregate, had a material adverse effect on our business, financial condition, results of operations or liquidity. There are no material pending or threatened legal proceedings at this time.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
    SEC EDGAROther events
  55. 55
  56. 56
  57. 57
    SEC EDGAROther events
  58. 58
  59. 59
  60. 60
    SEC EDGAROther events
  61. 61
  62. 62
    SEC EDGAROther events
  63. 63
    SEC EDGAROther events
  64. 64
  65. 65
  66. 66